Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | MMP14 | P50281 | 1/20 | 0.46 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4356243 | 1.00 | SPPL2A (0.48) | SPPL2AMAOBADAMTS4MMP2MMP13 | |
| SCHEMBL4349846 | 0.91 | MLNR (0.54) | SPPL2AMAOBADAMTS4MMP2MMP13 | |
| SCHEMBL4349850 | 0.91 | MLNR (0.54) | SPPL2AMAOBADAMTS4MMP2MMP13 | |
| SCHEMBL4346988 | 0.91 | ADAMTS4 (0.56) | SPPL2AADAMTS4MMP2MMP13MMP14 | |
| SCHEMBL4346985 | 0.91 | ADAMTS4 (0.56) | SPPL2AADAMTS4MMP2MMP13MMP14 | |
| SCHEMBL13617770 | 0.91 | SPPL2A (0.47) | SPPL2AMMP2MMP13 | |
| SCHEMBL4341210 | 0.87 | ABCB1 (0.55) | SPPL2AADAMTS4MMP2MMP13MMP14 | |
| SCHEMBL4341207 | 0.87 | ABCB1 (0.55) | SPPL2AADAMTS4MMP2MMP13MMP14 | |
| SCHEMBL2906364 | 0.85 | SPPL2A (0.56) | SPPL2A | |
| SCHEMBL2906368 | 0.85 | SPPL2A (0.56) | SPPL2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
| EP-1194404-B1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMA (US) | 2006-05-03 | — | — | EP | disclosed |
| US-6878728-B1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040122000-A1 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED. | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122000-A1 | Inhibitors of aspartyl protease | SPINT2, DNPEP, PRSS1 | SPPL2A 93/4885MAOB 4144/4885ADAMTS4 508/4885 |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | SPPL2A 93/4885MAOB 4144/4885ADAMTS4 508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.